Protox lines up $35M for BPH program

Warburg Pincus will invest up to $35 million in Canada's Protox Therapeutics, fueling its new therapy for benign prostatic hyperplasia as it advances into late-stage trials. The investment group will take a 21 percent stake in Protox in exchange for the first $10 million tranche. The additional money is scheduled to arrive in the next year. Story

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.